PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 31, Issue 6, 2003, Pages 467-473

  Mahe B ^a   Milpied, N ^a   Mellerin, M P ^a   Moreau, P ^a   Morineau, N ^a   Vigier, M ^a   Harousseau, J L ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Autologous stem cell transplantation; Follicular non Hodgkin's lymphoma; Residual disease

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN BCL 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD SAMPLING; BONE MARROW PURGING; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KAPLAN MEIER METHOD; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 0037366737     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703829     Document Type: Article

References (36)

1. Longo DL. What's the deal with follicular lymphomas? J Clin Oncol 1993; 11: 202-208.
2. Horning SJ. Treatment approaches to the low-grade lymphomas. Blood 1994; 83: 881-884.
3. Dana BW, Dahlberg S, Nathwani N et al. Long-term follow-up patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993; 11: 644-651.
4. Solal-Celigny P, Lepage E, Brousse N et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993; 329: 1608-1614.
5. Schouten C, Bierman J, Vaughan P et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989; 74: 2579-2584.
6. Colombat P, Donadio D, Fouillard L et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France autogreffe retrospective study of 42 patients. Bone Marrow Transplant 1994; 13: 157-162.
7. Haas R, Moos M, Karcher A et al. Sequential high-dose therapy with peripheral blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 13: 1685-1692.
8. Bastion Y, Price P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 8: 3257-3262.
9. Haas R, Moos M, Mohle R et al. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1996; 17: 149-155.
10. Bierman J, Vose M, Anderson R et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445-450.
11. Freedman S, Ritz J, Neuberg D et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 1991; 77: 2524-2529.
12. Rohatiner S, Johnson M, Price A et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177-1184.
13. Johnson PWM, Price CGA, Smith T et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1994; 12: 798-805.
14. Hardingham E, Kotasek D, Sage E et al. Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 1073-1076.
15. Freedman S, Gribben JG, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 7: 2780-2786.
16. Moos M, Schulz R, Martin S et al. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukemia 1998; 12: 1971-1976.
17. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 10: 3325-3333.
18. Apostolodis J, Gupta R, Grenzelias D et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 3: 527-536.
19. Horing SJ, Negrin RS, Hoppe RT et al. High dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97: 404-411.
20. Hardingham JE, Kotasek D, Sage RE et al. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation. Bone Marrow Transplant 1993; 11: 15-20.
21. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
22. Deisseroth AB, Zu Z, Claxton D et al. Genetic marding shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
23. Weiss LM, Warnhe RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 1987; 317: 1185-1188.
24. Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 12: 3275-3280.
25. Mahe B, Milpied N, Hermouet S et al. G-CSF alone mobilized sufficient peripheral blood CD 34+ cells for positive selection in newly diagnosed patients with myeloma and lymphoma. Br J Haematol 1996; 92: 263-268.
26. Kaplan E, Maier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-462.
27. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-168.
28. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525-1533.
29. Corradini P, Astolfi M, Cherasco C et al. Molecular monitoring of minimal residual disease in follicular and mantle cell Non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724-731.
30. Gribben JG, Neuberg D, Barber M et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83: 3800-3807.
31. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-3457.
32. Paryani SB, Hoppe RT, Cox RS et al. The role of radiation therapy in the management of stage III follicular lymphomas. J Clin Oncol 1984; 2: 841-848.
33. Nagler A, Acherstein A, Or R. Immunotherapy with recombinant human interleukin-2 and recombinant interferon alpha in lymphoma patients postautologous marrow on stem cell transplantation. Blood 1997; 89: 3951-3959.
34. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti CD20 antibody in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
35. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918-3924.
36. Price CGA, Meerabux J, Murtagn S et al. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol 1991; 9: 1527-1532.